Fingolimod, an approved immunomodulator for relapsing-remitting Multiple Sclerosis, exhibits complex and stage-dependent effects on neurotrophin pathways and motor behavior in Huntington’s disease mouse models. Here, BDNF is linked to juvenile Huntington disease.